Cantor Fitzgerald Reiterates $31.00 Price Target for Heron Therapeutics (HRTX)

Heron Therapeutics (NASDAQ:HRTX) has been assigned a $31.00 target price by investment analysts at Cantor Fitzgerald in a research note issued to investors on Friday. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 67.12% from the company’s previous close.

A number of other research analysts also recently issued reports on the stock. Oppenheimer restated a “buy” rating and issued a $27.00 price target on shares of Heron Therapeutics in a research report on Friday, November 10th. Northland Securities assumed coverage on shares of Heron Therapeutics in a research report on Wednesday, September 27th. They issued an “outperform” rating and a $40.00 price target on the stock. Mizuho assumed coverage on shares of Heron Therapeutics in a research report on Tuesday, September 26th. They issued a “buy” rating and a $28.00 price target on the stock. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a research report on Sunday, November 12th. Finally, ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $28.82.

Shares of Heron Therapeutics (NASDAQ:HRTX) opened at $18.55 on Friday. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62. Heron Therapeutics has a 1 year low of $12.21 and a 1 year high of $19.55. The company has a market cap of $1,190.52, a P/E ratio of -4.89 and a beta of 2.13.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The business had revenue of $8.57 million for the quarter, compared to the consensus estimate of $8.12 million. analysts predict that Heron Therapeutics will post -3.39 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its position in shares of Heron Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 2,383 shares during the period. Quantbot Technologies LP lifted its position in shares of Heron Therapeutics by 2,619.6% during the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares during the period. Trexquant Investment LP acquired a new position in shares of Heron Therapeutics during the 3rd quarter valued at $206,000. Jane Street Group LLC acquired a new position in shares of Heron Therapeutics during the 3rd quarter valued at $223,000. Finally, HighTower Advisors LLC lifted its position in shares of Heron Therapeutics by 11.4% during the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 1,700 shares during the period. Institutional investors own 98.78% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Reiterates $31.00 Price Target for Heron Therapeutics (HRTX)” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/06/cantor-fitzgerald-reiterates-31-00-price-target-for-heron-therapeutics-hrtx.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply